Publications by authors named "Andrew Lyne"

Claim this Profile
A
A freely precessing magnetar following an X-ray outburst.
Gregory Desvignes, Patrick Weltevrede, Yong Gao, David Ian Jones, Michael Kramer, Andrew G Lyne

Nat Astron· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19-induced postural orthostatic tachycardia syndrome treated with ivabradine.
Jenna Stephanie O'Sullivan, Andrew Lyne, Carl J Vaughan

BMJ Case Rep· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radio emission from a pulsar's magnetic pole revealed by general relativity.
Gregory Desvignes, Michael Kramer, Kejia Lee, Joeri van Leeuwen, Ingrid Stairs, Andrew Lyne

Science· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.
Jeffrey H Newcorn, Valerie Harpin, Michael Huss, Andrew Lyne, Vanja Sikirica

J Child Psychol Psychiatry· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Timothy E Wilens, Brigitte Robertson, Vanja Sikirica, Linda Harper, Joel L Young, Andrew Lyne

J Am Acad Child Adolesc Psychiatry· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
Mark A Stein, Vanja Sikirica, Margaret D Weiss, Brigitte Robertson, Andrew Lyne

CNS Drugs· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
Amaia Hervas, Michael Huss, Mats Johnson, Fiona McNicholas, Judy van Stralen, Andrew Lyne

Eur Neuropsychopharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of guanfacine extended release assessed during the morning, afternoon, and evening using a modified Conners' Parent Rating Scale-revised: Short Form.
Joel Young, Thomas Rugino, Ryan Dammerman, Andrew Lyne, Jeffrey H Newcorn

J Child Adolesc Psychopharmacol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design.
David R Coghill, Tobias Banaschewski, Michel Lecendreux, Mats Johnson, Alessandro Zuddas, Andrew Lyne

J Am Acad Child Adolesc Psychiatry· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
Ralf W Dittmann, Esther Cardo, Peter Nagy, Colleen S Anderson, Ralph Bloomfield, Andrew Lyne

CNS Drugs· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of the magnetic field structure of the Crab pulsar.
Andrew Lyne, Francis Graham-Smith, Patrick Weltevrede, Christine Jordan, Ben Stappers

Science· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
David Coghill, Tobias Banaschewski, Michel Lecendreux, Cesar Soutullo, Mats Johnson, Andrew Lyne

Eur Neuropsychopharmacol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bernard Lovell (1913-2012).
Francis Graham Smith, Rodney Davies, Andrew Lyne

Nature· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
Timothy E Wilens, Oscar Bukstein, Matthew Brams, Andrew J Cutler, Ann Childress, Andrew Lyne

J Am Acad Child Adolesc Psychiatry· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
Scott H Kollins, Frank A López, Bradley D Vince, John M Turnbow, Kimberly Farrand, Andrew Lyne

J Child Adolesc Psychopharmacol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.
Daniel F Connor, Robert L Findling, Scott H Kollins, Floyd Sallee, Frank A López, Andrew Lyne

CNS Drugs· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switched magnetospheric regulation of pulsar spin-down.
Andrew Lyne, George Hobbs, Michael Kramer, Ingrid Stairs, Ben Stappers

Science· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Floyd R Sallee, Andrew Lyne, Timothy Wigal, James J McGough

J Child Adolesc Psychopharmacol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
Floyd R Sallee, James McGough, Tim Wigal, Jessica Donahue, Andrew Lyne

J Am Acad Child Adolesc Psychiatry· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD.
J Biederman, Raun D Melmed, Anil Patel, Keith McBurnett, Jessica Donahue, Andrew Lyne

CNS Spectr· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Joseph Biederman, Raun D Melmed, Anil Patel, Keith McBurnett, Jennifer Konow, Andrew Lyne

Pediatrics· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.
Samuel W Boellner, Michael Pennick, Kimberly Fiske, Andrew Lyne, Amir Shojaei

Pharmacotherapy· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
James C Kisicki, Kimberly Fiske, Andrew Lyne

Clin Ther· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
Dennis Swearingen, Michael Pennick, Amir Shojaei, Andrew Lyne, Kimberly Fiske

Clin Ther· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Michael A Kamm, William J Sandborn, Miguel Gassull, Stefan Schreiber, Lechoslaw Jackowski, Andrew Lyne

Gastroenterology· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis